An active approach to wound healing

LeucoPatch® is a triple layer patch produced from the patient’s own blood without the addition of reagents or additives. Innovative and easy to use, LeucoPatch® is produced on demand in a disposable LeucoPatch® Device using the simple 3CP™ three step process over 20 minutes with minimal hands-on time. The patch then delivers active cells and growth factors key to wound healing.

The LeucoPatch® System

LeucoPatch® Device

The LeucoPatch® Device is a precision made mini cell-processor which, in combination with the LeucoPatch 3CP™ Centrifuge, is able to separate and concentrate cells, growth factors and signalling substances key to wound healing into a convenient to handle LeucoPatch.

3CP™ Centrifuge

The LeucoPatch 3CP™ Centrifuge works in combination with the LeucoPatch Device to produce a LeucoPatch. The process is simple and the processing time is short.


The LeucoPatch®

The 3 layer LeucoPatch® consists of fibrin for moisture retention and strength, platelets for growth factor release and leucocytes to orchestrate wound healing and to fight infection.

Easy to produce and easy to apply

A simple three step process

1. Collect blood

The patient’s blood is drawn into the sterile device with no additives.

2. Centrifuge

The LeucoPatch® is prepared by a two step centrifugation in 20 minutes.

3. Apply

LeucoPatch® is applied directly to the surface of the patient’s wound.

Product information Video – English
Produktinformationen Video – Deutsch

LeucoPatch® Cell Therapy

Normal wound healing

In normal wound healing, there is a shunting mechanism and nerve signals close vessels to force blood flow up to the skin, delivering cells and components important for wound healing. Upon wounding the arteriovenous (AV) shunts contract, leading to increased blood flow to the capillaries. In combination with capillary dilatation, leucocytes are recruited into the wound. This effective immune response leads to an inflammatory response able to clear potential infection, remove debris and orchestrate the healing process. This leads to the initiation of the proliferation phase, eventually leading to a healed wound.

AV shunting is part of the normal healing response. Immune cells, platelets and growth factors reach the wound.



Normal blood flow and good skin microcirculation. High availability of immune cells, platelets and growth factors.




Hard-to-heal ulcer

In hard-to-heal ulcers the capillary blood circulation is impaired, often due to nerve damage, as in diabetic foot ulcers where patients very often have neuropathy. The denervated arteriovenous (AV) shunts lose their normal contraction response and stay open, leading to blood bypassing the capillaries. This prevents important blood components from reaching the wound and as a result the sub-optimal inflammatory response is unable to clear infection and orchestrate the healing response. The wound stalls in a sub-optimal inflammatory phase and becomes chronic and hard-to-heal.

In neuropathic patients no shunting is seen, leading to a poor healing response.


Chronic Inflammation

Impaired blood flow - poor skin microcirculation. Low availability of immune cells, platelets and growth factors.


LeucoPatch treatment

LeucoPatch® is able to provide immune cells, platelets and growth factors and actively re-establish an optimal healing environment.






Diabetes is a condition you learn to live with, but a foot ulcer is different because it heavily affects your daily life. Now that the wounds have healed I can lead a normal life again, so it means a great deal for me.

Dorthe H. Larsen, Denmark


There is nothing I would rather do than help my patients, and it's terrible not to be able to do anything further for them when their wounds won't heal. LeucoPatch creates hope both for me as a nurse and my patients.

Lisbeth Vorbeck, Nurse, Copenhagen Wound Healing Center, Denmark


We have a great need for new approaches to the treatment of diabetic foot ulcers.  LeucoPatch is interesting because it is simple, logical and high-tech. We expect a lot of the large international randomised trial.

Bo Jørgensen, Doctor, Copenhagen Wound Healing Center, Denmark